STOK Director Alexander Cumbo Receives 39,674-Share Award

What Happened Alexander Cumbo, a director of Stoke Therapeutics, was granted an award on September 23, 2026, covering 39,674 shares. The Form 4 reports this as a derivative acquisition at $0.00 (i.e., an awarded option/award rather than an open-market purchase), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-09-23; Form 4 filed 2026-09-25 (timely filing).
• Award size: 39,674 shares reported as a derivative award at $0.00.
• Vesting: The award vests in 1/12th tranches quarterly on the 23rd of Dec/Mar/Jun/Sep, with the first tranche vesting Dec 23, 2026, subject to continued service (per footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of immediate sale or cashless exercise — these are restricted by vesting and service conditions.

Context This is a standard director equity award, not a market purchase or sale. Because the award vests over time and is subject to continued service, it does not represent an immediate buy or sell signal. Such grants are common compensation and should be interpreted accordingly by retail investors.